Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balram Bhargava

Showing results (171-180 of 191) with videos related to

Pageof 20
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|December 28, 2020
India Hypertension Control Initiative-Hypertension treatment and blood pressure control in a cohort in 24 sentinel site clinicsPrabhdeep Kaur, Abhishek Kunwar, Meenakshi Sharma, et al.
Plos Medicine|December 10, 2021
Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional studyManoj V Murhekar, Tarun Bhatnagar, Jeromie Wesley Vivian Thangaraj, et al.
The Lancet Regional Health. Southeast Asia|October 10, 2025
Seroprevalence of IgG antibodies against hepatitis-A infection among individuals aged 6-30 years in India, 2021: a nationwide population-based cross-sectional studyMuthusamy Santhosh Kumar, Chethrapilly Purushothaman Girish Kumar, Velusamy Saravanakumar, et al.
Pharmacoeconomics - Open|June 22, 2022
Cost of Surgical Care at Public Sector District Hospitals in India: Implications for Universal Health Coverage and Publicly Financed Health Insurance SchemesManinder Pal Singh, Shankar Prinja, Kavitha Rajsekar, et al.
Human Vaccines & Immunotherapeutics|March 21, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adultsPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
Circulation|September 15, 2021
Outcomes of Participants With Diabetes in the ISCHEMIA TrialsJonathan D Newman, Rebecca Anthopolos, G B John Mancini, et al.
JAMA Cardiology|February 28, 2019
Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical TrialJudith S Hochman, Harmony R Reynolds, Sripal Bangalore, et al.
Circulation|November 6, 2022
Survival After Invasive or Conservative Management of Stable Coronary DiseaseJudith S Hochman, Rebecca Anthopolos, Harmony R Reynolds, et al.
JAMA Cardiology|April 1, 2020
Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia: Secondary Analysis of the ISCHEMIA Randomized Clinical TrialHarmony R Reynolds, Leslee J Shaw, James K Min, et al.
The Lancet Regional Health. Southeast Asia|January 17, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyPrasad S Kulkarni, Abhijit Kadam, Sheela Godbole, et al.
Pageof 20

Showing results (171-180 of 191) with videos related to

Sort By:
Pageof 20
Journal of Clinical Hypertension (Greenwich, Conn.)|December 28, 2020
India Hypertension Control Initiative-Hypertension treatment and blood pressure control in a cohort in 24 sentinel site clinicsPrabhdeep Kaur, Abhishek Kunwar, Meenakshi Sharma, et al.
Plos Medicine|December 10, 2021
Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional studyManoj V Murhekar, Tarun Bhatnagar, Jeromie Wesley Vivian Thangaraj, et al.
The Lancet Regional Health. Southeast Asia|October 10, 2025
Seroprevalence of IgG antibodies against hepatitis-A infection among individuals aged 6-30 years in India, 2021: a nationwide population-based cross-sectional studyMuthusamy Santhosh Kumar, Chethrapilly Purushothaman Girish Kumar, Velusamy Saravanakumar, et al.
Pharmacoeconomics - Open|June 22, 2022
Cost of Surgical Care at Public Sector District Hospitals in India: Implications for Universal Health Coverage and Publicly Financed Health Insurance SchemesManinder Pal Singh, Shankar Prinja, Kavitha Rajsekar, et al.
Human Vaccines & Immunotherapeutics|March 21, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adultsPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
Circulation|September 15, 2021
Outcomes of Participants With Diabetes in the ISCHEMIA TrialsJonathan D Newman, Rebecca Anthopolos, G B John Mancini, et al.
JAMA Cardiology|February 28, 2019
Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical TrialJudith S Hochman, Harmony R Reynolds, Sripal Bangalore, et al.
Circulation|November 6, 2022
Survival After Invasive or Conservative Management of Stable Coronary DiseaseJudith S Hochman, Rebecca Anthopolos, Harmony R Reynolds, et al.
JAMA Cardiology|April 1, 2020
Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia: Secondary Analysis of the ISCHEMIA Randomized Clinical TrialHarmony R Reynolds, Leslee J Shaw, James K Min, et al.
The Lancet Regional Health. Southeast Asia|January 17, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyPrasad S Kulkarni, Abhijit Kadam, Sheela Godbole, et al.
Pageof 20